iShares U.S. Healthcare ETF News - August 5, 2026

AstraZeneca eyes $400B Bristol Myers Squibb merger, targeting oncology dominance

Britain's AstraZeneca is reportedly discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal values the combined company at nearly $400...